Clinical Trial Update: A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1B trial assessing the BTK inhibitor CC-292 in combination with lenalidomide in adults with relapsed/refractory B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CC-292
• Lenalidomide (lenalidomide)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Relapsed/Refractory B-cell Lymphoma | Phase 1 | Status: COMPLETED